Skip to content
    NUTX
    Earnings call· Jun 2026(Q2 FY26)

    Nutex Health Q2 FY26 earnings call NUTX

    Aug 7, 2026 Source

    Executive summary

    Nutex Health Q2 FY26 — Strong Financials and IDR Process Improvements Drive Growth

    Nutex Health delivered a strong financial performance in Q2 FY26, marked by significant net income and adjusted EBITDA growth, despite a revenue decline attributed to prior-year IDR collection adjustments. The company saw robust patient visit growth and improved operational efficiencies, benefiting from favorable federal court rulings and regulatory changes to the IDR process. Management is focused on internalizing real estate development and expanding service lines to drive future growth and shareholder value.

    Highlights

    5
    • Net income attributable to Nutex increased 3100% to $112.6 million for the first half of 2026.

    • Adjusted EBITDA increased 2% to $147.5 million for the first half of 2026, and 25.7% to $90 million in Q2 FY26.

    • Total patient visits increased 6.2% to 99,700 for the first half of 2026, with same-hospital visits up 3.4%.

    • Net cash from operating activities increased 40% to $109.7 million for the first half of 2026.

    • Gross profit for Q2 FY26 was $141.3 million, representing 67% of total revenue, up 15.8% YoY.

    Concerns

    3
    • Total revenue decreased 6% to $427.2 million for the first half of 2026 compared to $455.8 million in H1 FY25.

    • Q2 FY26 total revenue decreased 13.6% to $210.8 million compared to $244 million in Q2 FY25, primarily due to prior year's IDR collection adjustments.

    • Hospital division revenue decreased 14.6% to $201.9 million in Q2 FY26, with same hospitals down 12.1%.

    Guidance & targets

    3
    CategoryTargetConfidence
    New hospital openings
    3 to 5 hospitals per year
    high materiality
    High
    Arbitration-related costs
    25% to 30% decrease in historical normalized costs
    medium materiality
    High
    Arbitration-specific costs (as % of arbitration-related revenue)
    high teens to low 20s
    medium materiality
    High

    Segment performance

    2
    SegmentRevenueYoYQoQMargin
    Hospital Division
    Revenue decrease primarily due to larger positive adjustments in 2025 from the IDR process. Strong visit growth in Q2 and H1 2026, reflecting operational execution and internal investments.
    Same hospitals revenue decrease: 12.1% (Q2 FY26 vs Q2 FY25)Visits: 49,962 (Q2 FY26)Visits growth: 9.6% (Q2 FY26 vs Q2 FY25)Same hospital visits growth: 6.3% (Q2 FY26 vs Q2 FY25)Total revenue: $409.4M (H1 FY26)Total revenue decrease: 7% (H1 FY26 vs H1 FY25)Same hospitals revenue decrease: 6% (H1 FY26 vs H1 FY25)Total visits: 99,704 (H1 FY26)Total visits growth: 6.2% (H1 FY26 vs H1 FY25)Same hospital visits growth: 3.4% (H1 FY26 vs H1 FY25)
    $201.9M-14.6%
    Population Health Division
    Strong revenue growth for both Q2 and H1 2026. Most IPAs were profitable, with new IPAs in Dallas and San Antonio beginning patient enrollment in 2027.
    Revenue: $17.8M (H1 FY26)Revenue growth: 15% (H1 FY26 vs H1 FY25)Patients overseen: ~40,000IPAs profitable: Southern California, Houston, Phoenix (H1 FY26)IPAs cash flow negative: South Florida (H1 FY26)
    $8.9M16%

    Operational metrics

    17
    Adjusted EBITDA
    $147.5Mup 2% from $144.4M in H1 FY25
    H1 FY26

    Attributable to Nutex Health Inc.

    Adjusted EBITDA
    $90Mup 25.7% from $71.6M in Q2 FY25
    Q2 FY26

    Attributable to Nutex Health Inc.

    Cash and cash equivalents
    $205.2Mup 10.6% from $185.6M at Dec 31, 2025
    June 30, 2026

    Balance sheet remains very strong.

    Net income attributable to Nutex Health Inc. increase
    $83.5M
    Q2 FY26 vs Q2 FY25

    Net income for Q2 FY26 was $65.8M compared to a net loss of $17.7M for Q2 FY25.

    Gross profit increase
    15.8%
    Q2 FY26 vs Q2 FY25

    Gross profit for Q2 FY26 was $141.3M or 67% of total revenue, compared to $124.9M or 51.2% in Q2 FY25.

    Facility level operating costs and expenses as % of total revenue
    33%vs 48.8% in Q2 FY25
    Q2 FY26

    Total facility level operating costs and expenses were $69.5M in Q2 FY26 compared to $119.1M in Q2 FY25.

    Facility level operating costs and expenses as % of total revenue
    45.5%vs 46.6% in H1 FY25
    H1 FY26

    Total facility level operating and expenses were $194.2M for H1 FY26 compared to $212.5M for H1 FY25.

    Contract services cost decrease
    $52M
    Q2 FY26

    Decrease in contract services costs due to IDR rule changes and Halo MD contract amendment.

    G&A expenses as percentage of total revenue
    7.9%vs 5.1% in Q2 FY25
    Q2 FY26

    G&A expenses were $16.7M in Q2 FY26 compared to $12.5M in Q2 FY25.

    G&A expenses as percentage of total revenue
    7.3%vs 4.9% in H1 FY25
    H1 FY26

    G&A expenses were $31.1M in H1 FY26 compared to $22.5M in H1 FY25.

    Revenue per visit
    $5,185
    Q2 FY25

    This figure was higher due to early success with the IDR process and collection percentage adjustments.

    Cumulative net revenue per visit (IDR process start)
    $4,000 to $4,200
    July 2024 through June 2025

    More in line with current revenue per visit in 2026, reflecting stabilized collection percentages.

    Collection percentage
    80%up from 65% at Dec 31, 2024 and 75% by June 30, 2025
    Current

    Historical collection percentage leveled out to this average, leading to fewer revenue adjustments in 2026.

    Claims submitted through IDR process
    50% to 60%
    Ongoing

    Company continues to submit a significant portion of claims through the IDR process.

    IDR determination win rate
    over 85%
    Ongoing

    Company prevails in over 85% of IDR determinations.

    IDR collection rate (of determination wins)
    over 80%
    Ongoing

    Average collection rate for IDR determination wins.

    Employee turnover
    6.8%significantly below published hospital industry benchmarks
    H1 FY26

    Reflects workforce stability and competitive advantage.

    Industry KPIs

    5
    MetricValueDetails
    Utilization trends99,700visits
    Same facility volumes6.3%%
    Membership covered lives by line~40,000patients
    Segment revenue operating income$201.9MUSD
    Adjusted EPS EBITDA leverage guidance$147.5MUSD

    Deals & partnerships

    1
    Halo MDAmendment to original contract for dispute resolution services

    The amendment shifts the fee structure to a 'pay on collected' basis, retroactive to the original agreement in May 2024. It also favorably amended the service fee structure for net settlement amounts obtained on or after July 1, 2026. The renegotiation provides Nutex the right to perform dispute resolution services in-house or through other third-party vendors for certain future hospital facilities.

    Risks & headwinds

    2
    Revenue decline due to prior-year IDR collection adjustmentsH1 FY26 and Q2 FY26

    Total revenue decreased 6% to $427.2 million for H1 FY26 from $455.8 million in H1 FY25; Q2 FY26 total revenue decreased 13.6% to $210.8 million from $244 million in Q2 FY25.

    Mitigation: Stabilization of collection percentage at over 80% means fewer adjustments in 2026, leading to a more normalized revenue per visit going forward. Focus on increasing inpatient volume and service lines to drive future revenue growth.

    Insurer low payment strategy and slow in-network adoptionOngoing

    Insurers engage in consistent practice of submitting lowball offers; QPA still relatively low, leading to 50-60% of claims going through IDR.

    Mitigation: Leveraging the IDR process, which is reinforced by recent court rulings and regulatory changes, to secure fair, market-based reimbursement. Actively seeking in-network agreements while maintaining the ability to operate successfully out-of-network if terms are not favorable.

    What to watch in Q3 FY26

    4

    New hospital openings

    Next quarter
    Current3 hospitals expected to open in Q3/Q4 2026 (West Little Rock, San Antonio, Jacksonville)
    TargetConfirmation of Q3/Q4 2026 openings and progress on 2027 pipeline

    Why it matters

    New hospital developments are a key driver for long-term growth and shareholder value creation, expanding the company's footprint and patient reach.

    Looking ahead, our current pipeline in 2026 includes West Little Rock, Arkansas, San Antonio, Texas; and Jacksonville, Florida. All 3 are expected to open in the third and fourth quarter of 2026.

    Q&A highlights

    9

    What is the new go-forward rate for arbitration costs after the IDR ruling and Halo MD renegotiation, and is the Q2 revenue per visit a steady-state run rate?

    Arbitration-specific costs are expected to decrease from mid-20s percentage to high teens/low 20s. The Q2 revenue per visit is considered a fair run rate, consistent with the cumulative average since the IDR process began, with potential for slight increases due to more inpatient care.

    So normally, it was a range of in that mid 24% to 25%, 26 percentage in the past. Now currently, as we move forward, you should expect that to be just that specific piece probably down more into the high teens to low 20s comparatively.

    asked by Anderson Shack · answered by Unknown Executive

    3 min read6 chapters

    Detailed Narrative

    01

    IDR Process and Regulatory Environment

    The quarter saw significant developments in the Independent Dispute Resolution (IDR) process. Federal courts in multiple states issued rulings reinforcing the finality of IDR awards and limiting insurers' ability to challenge arbitration outcomes. Additionally, CMS and other federal agencies released final IDR rules on May 28, 2026, aimed at improving efficiency and transparency, including reducing the administrative fee from $115 to $15 per dispute. These changes are viewed as constructive for providers and are expected to streamline the process, underscoring CMS's intent for IDR to remain a key mechanism for fair reimbursement.

    02

    Halo MD Contract Amendment

    Nutex Health announced an amendment to its contract with Halo MD, shifting the fee structure to a 'pay on collected' basis, retroactive to the original agreement in 2024. This change, along with a favorably amended service fee structure for net settlement amounts, is expected to significantly reduce arbitration-related costs. The amendment also grants Nutex the flexibility to perform dispute resolution services in-house or use other third-party vendors for future facilities, providing greater control and cost management.

    03

    Hospital Development and Growth Pipeline

    The company is actively pursuing a de novo hospital development strategy, internalizing real estate capabilities for better control over timelines and costs. The current pipeline for 2026 includes new hospitals in West Little Rock, Arkansas; San Antonio, Texas; and Jacksonville, Florida, all expected to open in Q3 and Q4. For 2027, projects are planned in South, Central, and East Florida, as well as Oklahoma, with two initially owned and developed by Nutex. Beyond 2027, additional Nutex-owned and led projects are approved in Idaho, Florida, Pennsylvania, Ohio, and Arkansas, demonstrating a clear roadmap for long-term growth.

    04

    Operational Performance and Patient Experience

    Operational performance was strong, with total hospital visits increasing 6.2% to nearly 100,000 for the first half of 2026, and same-hospital visits growing 6.3% in Q2. The company continues to expand patient access and service lines, including the launch of endoscopy services. Patient satisfaction remains high, with an average Google rating of 4.8 stars across over 2,300 reviews. Employee turnover was low at 6.8% for the first half of 2026, significantly below industry benchmarks, contributing to consistent execution and high-quality patient care.

    05

    Population Health Division Progress

    The Population Health Management division now oversees nearly 40,000 patients, including Medicare Advantage, commercial, and Medicaid managed care members. Revenue for the division grew 15% for the first half of 2026. Independent Physician Associations (IPAs) in Southern California, Houston, and Phoenix were profitable, while South Florida was slightly cash flow negative. New IPAs in Dallas and San Antonio are contracting physicians and will begin enrolling patients in 2027, aiming to build strong partnerships and leverage existing hospital infrastructure.

    06

    Revenue Per Visit Dynamics

    The decrease in Q2 and H1 2026 revenue was primarily attributed to a larger positive increase in revenue recognized in H1 2025. This was due to adjustments in the collection percentage from 65% to 75% as historical collection data became available. With the collection percentage now stabilized at just over 80%, fewer such positive adjustments are recognized in 2026, leading to a more normalized revenue per visit. The cumulative net revenue per visit since the IDR process began in July 2024 has been consistent at $4,000 to $4,200.

    AI-generated summary of the company’s earnings call. Not investment advice.